Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Cathomas

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 2015
Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experienceC Chau, R Cathomas, M Wheater, et al.
Prostate Cancer and Prostatic Diseases|March 11, 2015
Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)M Joerger, R H N van Schaik, M L Becker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohortR Cathomas, D Klingbiel, T R Geldart, et al.
British Journal of Cancer|July 16, 2014
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumoursG Del Conte, C Sessa, R von Moos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2015
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)F Strasser, D Blum, R von Moos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2011
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)R von Moos, B Seifert, M Simcock, et al.
Prostate Cancer and Prostatic Diseases|March 1, 2017
Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter databaseD Keizman, M O Fosboel, H Reichegger, et al.
European Urology Oncology|March 20, 2026
Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14)S Gillessen, K Gobat, R Cathomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2025
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitorsE S M van Aken, B Devnani, A Prelaj, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 17, 2018
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-upF Honecker, J Aparicio, D Berney, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 2015
Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experienceC Chau, R Cathomas, M Wheater, et al.
Prostate Cancer and Prostatic Diseases|March 11, 2015
Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)M Joerger, R H N van Schaik, M L Becker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohortR Cathomas, D Klingbiel, T R Geldart, et al.
British Journal of Cancer|July 16, 2014
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumoursG Del Conte, C Sessa, R von Moos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2015
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)F Strasser, D Blum, R von Moos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2011
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)R von Moos, B Seifert, M Simcock, et al.
Prostate Cancer and Prostatic Diseases|March 1, 2017
Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter databaseD Keizman, M O Fosboel, H Reichegger, et al.
European Urology Oncology|March 20, 2026
Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14)S Gillessen, K Gobat, R Cathomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2025
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitorsE S M van Aken, B Devnani, A Prelaj, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 17, 2018
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-upF Honecker, J Aparicio, D Berney, et al.
Pageof 4